Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pamiparib

pamiparib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pamiparib

6 trials tracked of pamiparib.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 3
  1. Phase 2 Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors Completed
  2. Phase 2 Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Completed
  3. Phase 2 A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma Completed
  4. Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed
  5. Phase 1 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Completed
  6. Phase 1 Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial of oral pamiparib in recurrent ovarian cancer after prior PARPi exposure
Oncology Phase II
Phase II trial of oral pamiparib in recurrent ovarian cancer after prior PARPi exposure Pamiparib alone offers limited hope for ovarian cancer patients who have already tried other drugs
This prospective Phase II clinical trial enrolled 15 patients with recurrent ovarian cancer after prior PARPi exposure.
New data shows taking pamiparib by itself works for only a small number of women with recurrent ovarian cancer after other treatments failed
May 1, 2026